Latest news with #ADIANutrition
Associated Press
04-03-2025
- Business
- Associated Press
The Future of Stem Cell Investing: Spotlight on Smaller Innovators
The global stem cell therapy market is entering an era of unprecedented growth and innovation. Valued at $5.13 billion in 2024, the U.S. stem cell market alone is projected to reach $15.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.9%. Globally, the market is expected to hit $28.89 billion by 2030, fueled by advancements in regenerative medicine, increased government funding for research, and the development of groundbreaking therapies for conditions like cancer, autoimmune diseases, and genetic disorders. Stem cells, often called the body's internal repair system, have the unique ability to divide and regenerate, offering hope for treatments that address the root causes of diseases rather than just managing symptoms. From repairing damaged tissues to regenerating organs, the potential applications of stem cell therapies are vast and transformative. The U.S. Food and Drug Administration (FDA) has already approved several stem cell-based treatments, and the pipeline of new therapies continues to expand. This rapid growth is driven by several key factors: the rise of stem cell banks, increasing therapeutic potential, and a surge in research aimed at developing regenerative medicines. While large pharmaceutical companies and research institutions play a significant role, smaller biotech firms are also making important contributions, pushing the boundaries of what's possible in this dynamic field. In this piece, we explore some of the companies making waves in this exciting and rapidly evolving sector, highlighting their achievements, challenges, and potential to shape the future of medicine. ADIA Nutrition Inc. (OTC: ADIA) is on a mission to transform healthcare through innovation in regenerative medicine and premium organic supplements. Operating under two key divisions—its supplement arm and Adia Med, its medical division—the company is making waves in the fast growing global stem cell market. With cutting-edge therapies like Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT), ADIA Nutrition is empowering patients to address conditions ranging from autoimmune disorders to orthopedic injuries. 2025 has been a landmark year for ADIA Nutrition, with groundbreaking achievements that emphasize innovation and accessibility. In March, the company celebrated the FDA registration of Adia Vita, its premier stem cell product. This allows Adia Vita to be distributed nationwide, significantly expanding access to regenerative medicine. 'This acceptance reflects Adia Labs' commitment to broadening access,' said Larry Powalisz, CEO of ADIA Nutrition. The registration enhances patient access and opens new revenue opportunities. In February, ADIA announced a strategic expansion plan by partnering with elite Medical Spas to create satellite locations across the U.S. This low-cost model will offer treatments like UCB-SC therapies and stem cell injectables to health-conscious regions, tapping into an existing customer base and creating revenue streams via service fees, royalties, and equity interests. 'This expansion is a testament to our commitment to making therapies more accessible,' Powalisz said. The launch of Adia Labs LLC in February solidified ADIA's leadership in regenerative medicine. Adia Labs introduced AdiaVita, a high-potency stem cell product containing 100 million cells and 3 trillion exosomes per dose, designed for clinical research and therapeutic use. A future product, AdiaLink, will contain 3.5 trillion exosomes, pushing the boundaries of medical science. 'We are advancing medical science while maintaining the highest standards of safety and quality,' Powalisz stated. A key to ADIA's success is its partnership with a premier FDA-approved laboratory, ensuring the highest quality stem cell and exosome products. Each dose is third-party verified for purity, potency, and safety, making it a trusted choice for medical professionals. 'After months of due diligence, we offer the best quality therapies per treatment,' Powalisz noted. This partnership guarantees a steady supply of top-tier products. ADIA is also working to secure private insurance coverage for treatments like aHSCT and injectable stem cells, reducing the financial burden on patients and expanding access. 'Registering with the AHCA is a monumental step in providing open access to our therapies,' Powalisz said. The company's integration into the mainstream healthcare ecosystem is gaining traction, with several patients already preapproved by private insurers. The Winter Park, Florida clinic has exceeded financial expectations in its first month of operation, offering FDA-compliant treatments for conditions like Multiple Sclerosis, hip issues, and joint pain. 'Many patients have traveled abroad for treatments we now offer locally,' said Dr. Monica Sher, Chief Stem Cell Medical Officer at Adia Med. Looking ahead, ADIA plans to replicate its successful clinic model in new markets, expand satellite locations, and complete its uplisting to the OTCQB Venture Market. With aspirations for a Nasdaq listing, the company could be poised for significant growth. 'From January's financial win to February's breakthroughs, we're redefining healthcare possibilities,' Powalisz added. 'We're committed to innovation and sustainable growth.' For investors, ADIA offers a unique opportunity to be part of a company revolutionizing healthcare. With its innovative treatments, strategic partnerships, and commitment to quality, ADIA Nutrition is well-positioned to lead the regenerative medicine industry. CRISPR Therapeutics (NASDAQ: CRSP) is a biotechnology company that uses the CRISPR/Cas9 gene-editing tool to develop treatments for serious diseases. This powerful technology, which won a Nobel Prize, enables scientists to modify faulty genes that cause a variety of illnesses. The company made a major breakthrough in late 2023 when its first product, CASGEVY, became the first-ever CRISPR-based therapy to gain FDA approval. CASGEVY targets two blood disorders—sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)—by utilizing stem cells, marking a significant milestone in the practical application of gene editing. The launch of CASGEVY has been progressing well. By the end of 2024, over 50 treatment centers globally were set up to administer the therapy, and more than 50 patients had already begun the treatment process. The company anticipates further growth in patient enrollment in 2025, with clinical trials for children aged 5 to 11 now completed, with results expected later this year. In addition to CASGEVY, CRISPR Therapeutics is exploring ways to improve stem cell therapies, including developing methods that avoid the need for intensive pre-treatment steps. While the company is initially known for its blood disorder treatments, CRISPR Therapeutics is expanding its focus to other areas, such as cancer and autoimmune diseases. One promising program is CTX112, an advanced CAR T-cell therapy that uses modified immune cells to fight blood cancers. Early results from clinical trials have been promising, and the FDA has granted CTX112 a special designation to expedite its development. Updates on CTX112's progress are expected in mid-2025. CRISPR is also investigating the potential of CTX112 in treating autoimmune diseases, such as lupus, with more data anticipated in the coming months. CRISPR Therapeutics (NASDAQ: CRSP) is also looking into regenerative medicine, with one of its key initiatives, CTX211, aiming to treat Type 1 diabetes using stem cells. The goal is to enable patients to produce their own insulin, potentially eliminating the need for daily injections or long-term medication. Additional information on this program is expected in 2025. Financially, CRISPR Therapeutics is in a strong position, with approximately $1.9 billion in cash, providing a solid foundation for continued research and development. While CASGEVY's sales may face slow growth due to the complex nature of the treatment process, the company remains focused on long-term goals, developing transformative therapies that could significantly impact patients' lives. Despite challenges in the stock market, many analysts maintain an optimistic outlook for CRISPR Therapeutics. Some predict a potential 87% increase in its stock price within the next 12 months, especially if upcoming clinical trial results prove positive. With its innovative technology, diverse therapeutic pipeline, and solid financial backing, CRISPR Therapeutics (NASDAQ: CRSP) is well-positioned to remain a leader in gene editing and stem cell therapies. Mesoblast Limited (NASDAQ: MESO) is a biotech company focused on developing stem cell-based treatments for severe inflammatory diseases. One of its major advancements is RYONCIL, a mesenchymal stromal cell (MSC) therapy that received FDA approval in December 2024. RYONCIL is designed to treat steroid-refractory acute graft-versus-host disease (SR-aGvHD), a life-threatening condition in which a patient's immune system attacks the body after a bone marrow transplant. In clinical trials, RYONCIL demonstrated a 70% response rate, with 49% of patients surviving for four years. The therapy is priced at $194,000 per infusion and is available through Mesoblast's MyMesoblast patient services hub, with distribution managed by Cencora. Mesoblast is also expanding the use of its stem cell technology for other conditions. The company is testing RYONCIL in pediatric patients with Crohn's disease, a severe inflammatory bowel disease. Early studies in adults have shown promising results, and Mesoblast plans to extend testing to children who have not responded to other treatments. Additionally, Mesoblast is developing REVASCOR, a stem cell therapy aimed at treating heart failure. In 2024, the FDA supported an accelerated approval pathway for REVASCOR in patients with end-stage heart failure who rely on mechanical heart pumps. Mesoblast is also researching REVASCOR for children with hypoplastic left heart syndrome (HLHS), a rare heart condition, which could open the door to further FDA approvals. On the financial front, Mesoblast is in a relatively strong position. The company raised $161 million in a private placement, leaving it with approximately $200 million in cash to support its ongoing research and development activities. Mesoblast has also reduced its operating expenses by 22% from the previous year, indicating improved financial management. With the FDA-approved RYONCIL and a pipeline of other promising therapies, Mesoblast appears positioned to continue its work in stem cell-based treatments. bluebird bio, Inc. (NASDAQ: BLUE), founded in 2010, has been a significant player in the field of gene therapy, focusing on developing treatments for severe genetic diseases like sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Over the years, the company has received FDA approvals for three gene therapies, positioning itself as a leader in the space. However, despite its scientific accomplishments, bluebird bio has faced substantial financial challenges, leading to its decision to go private in 2025. In early 2025, bluebird bio announced an agreement to be acquired by global investment firms Carlyle Group Inc. and SK Capital Partners, along with a team of biotech executives. Under the terms of the deal, bluebird bio's stockholders will receive $3.00 per share in cash, with the potential for additional payouts of up to $9.84 per share through a contingent value right, depending on the performance of its product portfolio. The acquisition, expected to close in the first half of 2025, will provide bluebird bio with the capital needed to scale the commercial delivery of its gene therapies. 'For more than a decade, bluebird has been at the forefront of gene therapy, delivering treatments to patients facing life-threatening genetic diseases,' said Andrew Obenshain, CEO of bluebird bio. 'However, as financial challenges mounted, it became clear that securing the right strategic partner was critical to maximizing value for our stockholders and ensuring the long-term future of our therapies.' The acquisition arrives at a difficult time for bluebird bio. The company has faced mounting financial pressures, including the denial of a priority review voucher by the FDA and the risk of loan default. By partnering with Carlyle and SK Capital, bluebird bio aims to secure the necessary resources to continue its operations and bring its therapies to patients. Upon completion of the deal, bluebird bio will no longer be publicly traded, and former Mirati Therapeutics CEO David Meek is expected to take over as the new CEO. bluebird bio has achieved notable scientific milestones, particularly with its LYFGENIA (lovotibeglogene autotemcel, or lovo-cel) gene therapy for sickle cell disease. At the 66th American Society of Hematology (ASH) Annual Meeting in December 2024, the company presented long-term data showing that LYFGENIA significantly reduces or eliminates vaso-occlusive events (VOEs) in patients with sickle cell disease. Among the 58 patients treated in the HGB-206 and HGB-210 studies, 94.7% achieved complete resolution of severe VOEs, with benefits sustained for a median of over four years. Notably, patients with a history of overt stroke, a severe complication of sickle cell disease, remained stable without recurrent strokes for up to nine years post-treatment. These results highlight the therapy's potential to address the underlying cause of the disease. Despite these scientific successes, bluebird bio's financial struggles highlight the challenges of commercializing high-cost gene therapies, particularly in a complex reimbursement environment. The decision to go private reflects the difficulties in balancing innovation with financial sustainability. While its shares will soon be removed from public trading, bluebird bio's contributions to the field of gene therapy remain significant. Its therapies have provided new treatment options for patients with severe genetic conditions, and its ongoing research continues to advance gene therapy science. As the company transitions to private ownership, its focus on delivering innovative treatments to patients will remain central to its mission. Disclaimers: RazorPitch Inc. 'RazorPitch' is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact Email: Send Email City: NAPLES State: Florida Country: United States
Yahoo
28-02-2025
- Business
- Yahoo
ADIA Nutrition Inc. Ignites 2025 with February Breakthroughs, Riding Adia Med's Profitable January Triumph
Winter Park, Florida--(Newsfile Corp. - February 28, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a pioneer in healthcare innovation and regenerative medicine, concludes an extraordinary February with groundbreaking advancements in stem cell therapies, strategic partnerships, and a pivotal corporate milestone. These achievements, layered atop January's financial triumph at the Adia Med Winter Park Clinic, underscore ADIA Nutrition's unstoppable momentum toward revolutionizing healthcare, enhancing investor visibility, and delivering cutting-edge solutions nationwide. February's transformative journey began on February 3, when Adia Med, the medical division of ADIA Nutrition, officially entered the $15.1 billion global stem cell market. Offering FDA-compliant treatments using 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps), the clinic leverages high-quality umbilical cord stem cells to address conditions like inflammation, autoimmune disorders, and orthopedic issues-providing a U.S.-based alternative to international hubs like Panama and Switzerland. On February 5, the company took a significant step toward uplisting from OTC Pink to the OTCQB Venture Market by appointing a PCAOB-registered accounting firm for a third-party audit, boosting transparency and laying groundwork for a future Nasdaq Small Cap listing. The month gained further traction mid-February. On February 11, ADIA Nutrition tackled historical share issuance concerns, pledging to retire over 25 million undocumented shares-cutting outstanding shares by approximately 15 percent-and reinforcing its commitment to shareholder integrity. On February 13, Adia Med advanced its registration with Florida's Agency for Health Care Administration (AHCA), aiming to secure private insurance coverage for therapies like Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and stem cell injectables, enhancing affordability. On February 18, a partnership with a premier FDA-approved laboratory ensured a steady supply of top-tier umbilical cord stem cell and exosome products, featuring 100 million viable cells and 3 trillion exosomes per dose, cementing Adia Med's leadership in regenerative medicine quality. February's pinnacle arrived with three standout milestones that underscored ADIA Nutrition's rapid progress in regenerative medicine and corporate growth. These achievements highlighted the company's innovation, scalability, and commitment to enhancing investor confidence, marking a transformative close to the month. February's Standout Milestones: February 20: ADIA Nutrition launched Adia Labs LLC, unveiling Adia Vita-a branded stem cell product containing 100 million viable cells and 3 trillion exosomes per dose for clinical research and therapeutic use, targeting a market of over 1 million doctors and clinics. February 24: Adia Med announced a nationwide expansion plan, partnering with elite Medical Spas to create satellite locations in health-conscious regions, offering a scalable, low-risk model to boost revenue and service reach. February 26: ADIA Nutrition achieved a critical corporate victory as OTC Markets removed its shell risk designation, a key requirement for OTCQB uplisting, expedited through close collaboration with OTC Markets, highlighting the company's operational integrity and accelerating its path to greater liquidity and investor trust. These February triumphs build on January's success, when the Adia Med Winter Park Clinic exceeded financial expectations in its first operational month, covering all opening expenses with surplus revenue. Treating conditions like Multiple Sclerosis (MS), hip issues, torn tendons, and joint pain with umbilical cord stem cells (UCB-SC), the clinic demonstrated the wide-reaching impact of its regenerative therapies. "January's financial strength gave us a solid base, and February's leaps-including the shell risk removal and Adia Labs' progress-propel us forward," said Larry Powalisz, CEO of ADIA Nutrition. "We're thrilled to thank OTC Markets for their swift support in clearing this hurdle, allowing me to share exciting updates with our investors that I couldn't before. This is just the start." The OTCQB uplisting process, now in clear sight with the shell risk designation lifted, will elevate ADIA Nutrition's visibility to a broader investor audience. The Med Spa partnerships will efficiently scale operations, while the lab collaboration ensures product excellence. The share retirement effort further solidifies corporate governance, amplifying investor confidence, as ADIA Nutrition strengthens its position as a leader in regenerative medicine innovation. Looking forward, ADIA Nutrition plans to replicate the Winter Park Clinic model in new markets, expand satellite locations, and complete its OTCQB uplisting with Nasdaq aspirations on the horizon. These efforts promise enhanced shareholder value and cutting-edge care for diverse communities. "From January's financial win to February's strategic breakthroughs, we're redefining healthcare possibilities," Powalisz added. "We're committed to innovation, accessibility, and sustainable growth for our stakeholders." For questions, inquiries, or further information, contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:ADIA Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, it operates two key divisions: a supplement division offering premium, organic supplements, and a medical division establishing clinics specializing in leading-edge stem cell therapies, including Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these efforts, ADIA Nutrition empowers individuals to live their best lives by addressing nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor:This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current plans and expectations and are subject to uncertainties and risks that could significantly affect the company's plans, expectations, and future results. A detailed list of risks and factors is available in reports filed with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to update or revise these statements due to new information, future events, or otherwise. To view the source version of this press release, please visit
Yahoo
24-02-2025
- Business
- Yahoo
ADIA Nutrition Inc. Embarks on Nationwide Expansion of Adia Med Satellite Locations
Winter Park, Florida--(Newsfile Corp. - February 24, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in healthcare innovation and regenerative medicine, proudly announces its strategic expansion plan for Adia Med satellite locations across the United States. This initiative aims to make Adia Med's innovative treatments more accessible by partnering with premier Medical Spas dedicated to anti-aging, wellness, and body repair. ADIA Nutrition Inc. Embarks on Nationwide Expansion of Adia Med Satellite LocationsTo view an enhanced version of this graphic, please visit: ADIA Nutrition will collaborate with elite Med Spas, leveraging their established infrastructure, reputation, and customer base to introduce Adia Med's advanced treatments. This partnership model creates a beneficial synergy for both partners, enhancing the service offerings of the Med Spas while broadening Adia Med's reach. The expansion will initially target regions where there's a high demand for longevity, anti-aging, and regenerative treatments, focusing on major cities and affluent suburbs known for their health-conscious demographics. Satellite locations will offer a curated selection of Adia Med's services, including Umbilical Cord Stem Cell (UCB-SC) therapies, stem cell injectables, and other regenerative solutions, which will complement and enhance the existing Med Spa services, providing a comprehensive approach to health and beauty. To maintain the high standard of care, ADIA Nutrition will provide comprehensive training for Adia's medical professionals alongside rigorous quality control measures. This ensures that the integrity and effectiveness of Adia Med treatments remain consistent across all locations. The expansion will proceed in phases, starting with pilot programs to refine the operational model before a broader rollout, ensuring each step leverages the success of the previous. Investment and Growth Potential By partnering with Med Spas, Adia Med can significantly expand its market presence with reduced overhead costs, offering Adia a model with lower risk and high scalability. This approach introduces multiple revenue streams through service fees, royalties, and potential equity interests, creating a robust financial framework. The synergy between Adia Med and its Med Spa partners not only increases market penetration but also enhances revenue potential by tapping into an already engaged clientele interested in wellness and anti-aging solutions. Larry Powalisz, CEO of ADIA Nutrition, stated, "Here is a piece of the roadmap of our expansion as promised. This expansion into satellite locations through strategic partnerships with premier Med Spas is a testament to our commitment to making our life-changing therapies more accessible. We believe this model not only accelerates our growth but also aligns perfectly with our vision for regenerative medicine." This strategic expansion lays the groundwork for future product and service introductions, utilizing the existing network for rapid market adoption and providing valuable feedback for continuous innovation. ADIA Nutrition invites current and potential shareholders to follow this exciting development, promising to redefine healthcare accessibility and efficacy. Larry Powalisz also highlighted that the success of this initiative stems from the mutual benefits it offers; every successful Med Spa will significantly benefit from Adia Med's ability to help existing patients and attract new ones, bolstered by a generous commission structure that ensures financial benefits for all parties involved. For inquiries or further information, Med Spas and medical professionals are encouraged to contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
20-02-2025
- Business
- Yahoo
ADIA Nutrition Proudly Launches Adia Labs LLC and Begins Sales of Branded Stem Cell Products
Winter Park, Florida--(Newsfile Corp. - February 20, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a trailblazer in healthcare and supplementation, proudly announces the launch of Adia Labs LLC, a new division dedicated to advancing regenerative medicine. This initiative underscores ADIA Nutrition's commitment to providing high-quality products for the research and medical community. To view an enhanced version of this graphic, please visit: Introducing Adia Labs LLC: Adia Labs focuses on delivering premium regenerative medicine solutions, specifically tailored for clinical research, studies, and trials. The division introduces: AdiaVita: A private-label product featuring umbilical cord stem cells. Each unit of AdiaVita guarantees a minimum of 100 million viable cells and 3 trillion exosomes, designed to support advanced medical research and therapeutic applications. This product has undergone rigorous third-party verification to ensure unparalleled quality, purity, and potency. AdiaLink: Coming soon, this product will offer exosomes with a guaranteed count of 3.5 trillion per unit. It's specifically crafted for exclusive use in clinical studies, trials, and research by doctors and clinics, aiming to push the boundaries of medical science. The establishment of Adia Labs was made possible through a groundbreaking deal with an esteemed FDA-approved laboratory. This partnership allows ADIA Nutrition to offer AdiaVita under its own brand, ensuring that the products meet the highest standards of efficacy and safety. This collaboration leverages the lab's expertise in stem cell technology, reinforcing ADIA Nutrition's mission to provide cutting-edge, quality-driven health solutions. Larry Powalisz, CEO of ADIA Nutrition, stated, "Our expansion into regenerative medicine is more than just growth; it's a step towards redefining healthcare. With Adia Med and now Adia Labs, we are dedicated to advancing medical science while maintaining the highest standards of quality and safety. Through our research, we estimate that we have over one million doctors and/or clinics as our potential client base." Adia Labs is set to meet the growing demand for non-invasive, biological treatments for various conditions, including autoimmune diseases, degenerative disorders, and recovery from injuries. With its unique composition, Adia Labs aims to offer an accessible and effective solution for those seeking the benefits of stem cell therapy. Doctors and clinics nationwide can now purchase these umbilical cord stem cell and exosome products for research, trials, and studies from Adia Labs. For pricing and further information, they should visit With stem cells, Adia Med opens new avenues for repairing and regenerating damaged tissues, providing hope for various health conditions such as autoimmune or cognitive diseases. This launch not only expands ADIA Nutrition's product line but also positions them at the forefront of regenerative medicine, promoting a future where innovative treatments are more accessible and effective. For media inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
11-02-2025
- Business
- Yahoo
ADIA Nutrition Inc. Identifies Historical Share Issuance Issues; Commits to Retiring over 25 Million Shares
Winter Park, Florida--(Newsfile Corp. - February 11, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in health and wellness solutions, has uncovered issues with share issuance from over a decade ago. Following an internal review, it was discovered that around 25 million shares were either issued or committed without proper documentation. This includes 15 million shares currently outstanding and 10 million shares promised in an agreement to pay, prior to the current board's tenure. ADIA Nutrition is now actively working to retire these shares which would decrease the current number of outstanding shares by approximately 15 percent. OTC MarketsTo view an enhanced version of this graphic, please visit: ADIA's Current Share Structure (as recorded by OTC Markets): Outstanding: 95,899,861 Restricted: 74,051,080 Unrestricted: 21,848,781 Held at DTC: 19,575,347 Float: 13,848,781 The company's accountants and board are also examining other outstanding restricted shares that might have been improperly issued before the current board assumed control. After a detailed review of its shareholder structure, ADIA Nutrition confirmed that these shares lacked the required legal documentation and regulatory filings. Larry Powalisz, CEO of ADIA Nutrition Inc., commented, "We have taken immediate steps to correct this past oversight. Ensuring the integrity and legality of our share structure is crucial for our commitment to transparency. We are collaborating closely with our legal advisors to retire these shares appropriately." Steps Being Taken Include: Investigation: A comprehensive review of historical records to understand how the undocumented issuance occurred. Compliance: Working with legal experts to ensure all share retirement complies with regulatory requirements. Transparency: Engaging in direct communication with shareholders to keep them informed about the actions being taken. This initiative will not impact ADIA Nutrition's operational capabilities or its strategic focus on health and wellness. The company continues its commitment to innovation in areas like umbilical cord stem cell treatments and Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis. For media inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in Hematopoietic Stem Cell Transplantation (HSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
